Drug Trial Radar · NCT07703956
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Oct 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase.
Conditions
- Schizophrenia
Interventions
VV119 2mgDrug
VV119 capsules 1 capsule (2mg/capsule) + VV119 capsules placebo 2 capsules + aripiprazole tablet placebo 2 tablets
VV119 4mgDrug
VV119 capsules 2 capsules (2mg/capsule) + VV119 capsules placebo 1 capsules + aripiprazole tablet placebo 2 tablets
VV119 6mgDrug
VV119 capsule 3 capsules (2mg/capsule) + aripiprazole tablet placebo 2 tablets
Aripiprazole tabletDrug
VV119 capsule placebo 3 capsules (2mg/capsule) + aripiprazole tablet 2 tablets
PlaceboDrug
VV119 capsule placebo 3 capsules (2mg/capsule) + aripiprazole tablet placebo 2 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6Time frame: Baseline and Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.